Tumor Innate Immune Surveillance

Dear Colleagues,

Key immune evasion mechanisms in established tumors have been well characterized, culminating with the clinical approval of several drugs targeting T cell immune checkpoints (ICP). By contrast, while the concept of tumor immune surveillance is well accepted, the very early events that permit immune sensing of pre-neoplastic cells remain poorly understood. The objective of this Special Issue is to gather original studies and reviews addressing immune sensing mechanisms of early cell transformation. The Special Issue is expected to assemble studies analyzing interactions between cells undergoing transformation and innate immune cells based on in vitro and/or in vivo models. Studies on conventional T/B cells are out of the scope of this Special Issue. Of specific interest are studies deciphering the role in the detection of early cell transformation of specific immune cell types, such as dendritic cells, macrophages, neutrophils, and other myeloid cells, and of innate lymphoid cells, including unconventional T cells (NKT, gdT cells) and NK cells. Further, studies deciphering tumor intrinsic molecular mechanisms (i.e., senescence, cellular stresses such as the UPR, Genomic stress) or intracellular sensors (Sting, RIG-I, etc.) leading to early immune alert are welcome.

Dr. Christophe Caux
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.